Pharma Process Analytics Patents: Who Leads, Where the Gaps Are 2026
- Filings nearly quadrupled from 2021 to 2024, rising from 4 to 15 records — the strongest three-year run in this dataset, though 2025-2026 figures are still filling in due to publication lag.
- One assignee dominates the ranked leaders, holding 78 of the ranked filings while the rest of the field is a short tail of much smaller players.
- G01N material analysis and G01J light measurement dominate the IPC mix, covering 92.6% and 76.6% of the 94 records respectively, pointing to spectroscopic and analytical-instrument claims as the core of this space.
Filing growth compares 2021 (4 records) with 2024 (15) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field.
What this landscape covers
This review covers 94 published patent records filed against a search combining pharmaceutical process analytics, monitoring and control with the enabling measurement techniques behind them: inline measurement, process spectroscopy, critical process parameters, multivariate analysis, real-time release and chemometric modelling. The scope runs from 2015 through the 2026-08-31 data cut-off, capturing both the instrumentation side — light sources, spectroscopic detectors, fiber delivery — and the software layer that turns raw signal into a release decision.
Filing activity is concentrated overwhelmingly in the United States receiving office, with much smaller volumes routed through WIPO's PCT system, Australia, Europe, Israel and India. That distribution suggests the technology is being protected first and most heavily in the US market, with international filing used selectively rather than as a default strategy.
Filing trend and technology composition
Two views of the same 94-record dataset: how filing volume has moved year over year, and which IPC subclasses the claims actually sit in.
Filing trend, 2017-2026
Annual filings rose from 6 in 2017 to a peak of 15 in 2024, including a jump from 4 filings in 2021 to that 2024 peak — a +275% increase over three years. 2025 and 2026 show fewer published records, but publication typically lags filing by around 18 months, so those most recent years understate actual filing activity rather than signalling a slowdown.
IPC subclass composition
G01N (material analysis and testing) appears in 92.6% of the 94 records and G01J (radiation and light measurement) in 76.6%, confirming that most filings combine an analytical measurement claim with a spectroscopic detection method. A61B (diagnosis and surgery, 73.4%) and G16H (healthcare informatics, 53.2%) show the field also reaches into diagnostic devices and data-management layers, while H01S (lasers, 52.1%) underlines how central light-source engineering is to the inline measurement approach.
Shares are the percentage of the 94 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Pharma Process Analytical Technology Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about pharma process analytical technology patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records in this landscape
Short-wave infrared super-continuum lasers for natural gas leak detection, exploration, and other active remote sensing applications
A measurement system built around semiconductor light sources that multiplex an input optical beam into an intermediate beam, then deliver it through fused-silica fiber to produce an output beam spanning 700-2500 nanometers with at least 10 nanometers of bandwidth. A measurement apparatus directs this output to a sample to generate a spectroscopy signal, which a receiver processes into an output reading — the same broadband light-source architecture that underlies several of the highest-cited records in this dataset.Filed by Omni MedSci, Inc., published 2018-05-03.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20140183362A1 | Short-wave infrared super-continuum lasers for detecting counterfeit or illicit drugs and pharmaceutical proc… | 76 |
| 2 | US9651533B2 | Short-wave infrared super-continuum lasers for detecting counterfeit or illicit drugs and pharmaceutical proc… | 71 |
| 3 | US10213113B2 | Physiological measurement device using light emitting diodes | 58 |
| 4 | US11160455B2 | Multi-wavelength wearable device for non-invasive blood measurements in tissue | 51 |
| 5 | US20150316415A1 | Short-wave infrared super-continuum laers for natural gas leak detection, exploration, and other active remot… | 43 |
| 6 | US20230172455A1 | Short-wave infrared sensor for identifying based on water content | 40 |
| 7 | US11564577B2 | Wearable device coupled to time-of-flight imaging system | 39 |
| 8 | US10098546B2 | Wearable devices using near-infrared light sources | 39 |
| 9 | US11678805B2 | Active remote sensing system using time-of-flight sensor combined with cameras and wearable devices | 38 |
| 10 | US20050273267A1 | Method for identifying markers | 35 |
Citation counts reflect influence within the searched corpus and skew toward older filings; treat them as a signal of prior influence rather than current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three patterns stand out once the ranking, the IPC mix and the trend line are read together.
Growth is real but recent years are incomplete
Filings climbed from 4 in 2021 to a peak of 15 in 2024. Because publication lags filing by roughly 18 months, the 2025-2026 dip in the chart reflects the reporting window, not a cooling of interest — any read of momentum should anchor on 2024 as the last complete year.
One assignee holds most of the ranked filings
The assignee ranking returns only four companies, and the leader accounts for 78 records against a long tail of far smaller filers. That is a narrow ranked field rather than a broad competitive set, which matters when assessing freedom to operate.
Spectroscopic measurement is the technical center of gravity
Nearly all records touch material analysis (G01N) and light measurement (G01J) together, meaning most claims pair a chemometric or multivariate analysis step with an optical detection method rather than treating them as separate inventions.
Even the leader's pace has slowed in the most recent tracked year
The leading assignee shows only 1 filing in the latest year, down 50% year over year, while the two smaller ranked assignees show none. Given publication lag, this is consistent with a filing pause showing up early rather than a confirmed retreat.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to pharma process analytical technology patent landscape, with the prior art for and against each one.
Who is filing, and where the field is thin
The ranked assignee set for this search is small: four companies, headed by one filer with a clear lead and two others contributing single-digit or co-filed records.
Omni MedSci anchors the field
Omni MedSci holds the large majority of ranked filings, built around short-wave infrared super-continuum laser sources and their application to spectroscopic measurement, including pharmaceutical process control claims. Its recent-year filing count fell 50% year over year, which given publication lag may understate current activity.
SeropTix pairs with an individual inventor-assignee
SeropTix Inc's strongest co-assignee link in this dataset is a single shared record with Maione Theodore E, the strongest co-assignee pair identified in the search. Neither shows filings in the latest tracked year.
The ranking is short, not exhaustive of the field
This is the complete ranked assignee list the dataset returns for this search string — not a top-50 or top-100 cut. A short ranked list alongside 94 total records implies many records sit with unranked or unassigned filers outside these four names.
| Assignee | Recent year | YoY |
|---|---|---|
| OMNI MEDSCI INC | 1 | -50% |
| SEROPTIX INC | 0 | — |
| MAIONE THEODORE E | 0 | — |
Where to take this analysis
The dataset points to a narrow set of active filers and a spectroscopy-heavy claim base. Two directions are worth pursuing next.
Check freedom to operate against the leading assignee's laser and spectroscopy claims
With one assignee holding 78 of 94 ranked records, any new inline-measurement or super-continuum laser filing should be checked directly against that portfolio before drafting.
Run a claim comparison in Eureka →Map the under-claimed branches before committing claim language
Sub-areas like dental-application monitoring and specific-application computing for critical process parameters show thinner coverage than the spectroscopy core, and may offer more room to file distinct claims.
Explore white space in Eureka →Common questions about this landscape
The assignee ranking for this dataset returns only four companies, with one — Omni MedSci — holding the large majority of ranked records at 78 out of 94. The remaining ranked assignees, SeropTix Inc and Maione Theodore E, contribute far smaller counts and share at least one co-filed record. Because the ranking is short rather than a top-50 or top-100 cut, a meaningful share of the 94 total records likely sits outside these four named filers, so this list should be read as the ranked leaders, not the whole competitive field.
Filings grew substantially between 2021 and 2024, rising from 4 to 15 records, a +275% increase that marks the peak year in this dataset. The apparent decline in 2025 and 2026 should not be read as slowing interest: patent publication typically lags the actual filing date by around 18 months, so the most recent one to two years in any filing trend are structurally incomplete. 2024 is the last year in this dataset that can be treated as a complete picture.
Material analysis and testing (IPC class G01N) appears in 92.6% of the 94 records, and radiation and light measurement (G01J) in 76.6%, meaning the large majority of filings combine an analytical measurement claim with an optical or spectroscopic detection method. Diagnosis and surgery devices (A61B) and healthcare informatics (G16H) also feature heavily, at 73.4% and 53.2% respectively, showing the field extends from raw instrumentation into diagnostic and data-management applications. Laser and light-source engineering (H01S) is present in just over half of records, underlining how central broadband light sources are to the inline measurement approach used across this landscape.
US20180120280A1, assigned to Omni MedSci, Inc. and published 2018-05-03, describes a measurement system using semiconductor light sources multiplexed into an intermediate optical beam, delivered through fused-silica fiber to produce an output beam spanning 700 to 2500 nanometers with at least 10 nanometers of bandwidth, which is then directed at a sample to generate a spectroscopy signal for processing. This claim structure sits at the core of the broadband short-wave infrared measurement approach that recurs across several of the most-cited records in this dataset. Anyone developing inline spectroscopic measurement using a similarly broad, multiplexed light-source architecture in that wavelength range should review this filing and its related family members closely before drafting claims of their own.
The IPC composition shows spectroscopic measurement (G01N, G01J) and diagnostic devices (A61B) as heavily claimed, while sub-areas such as dental-application process monitoring, structural or mechanical testing balance under multivariate analysis, and specific-application computing tied to critical process parameter tracking appear less frequently relative to that core. These thinner branches do not mean lower commercial value; they suggest less-crowded claim space where a well-drafted first claim has more room before running into the dominant assignee's existing spectroscopy portfolio. Given how concentrated the ranked leaders are around laser-based measurement, software and workflow claims built on top of that hardware layer may be a more open path than the optical measurement claims themselves.
Research Pharma Process Analytical Technology Patent Landscape in depth with Eureka
Go past this page: query the whole pharma process analytical technology patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.